You are here

  • Home
  • Archive
  • Volume 17, Issue 2
  • In two parallel pragmatic equivalence trials, leukotriene receptor antagonists as initial therapy for asthma compared with inhaled corticosteroids and as add on therapy to ICS compared with adding long-acting β agonists provided equivalent short-term ast…

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
In two parallel pragmatic equivalence trials, leukotriene receptor antagonists as initial therapy for asthma compared with inhaled corticosteroids and as add on therapy to ICS compared with adding long-acting β agonists provided equivalent short-term asthma quality of life but were associated with more medication switches

http://dx.doi.org/10.1136/ebm.2011.100140

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests Yes – JMFG has received fees from AstraZeneca, GSK, Merck, BI and Novartis and Nycomed for lectures, advisory committees, travel grants or consultancy services. He has also received fees or grants paid and used for research, education, equipment or salaries from GSK, BI, Wyeth, Genentech, Topigen, Canadian Institute for Health Research, Medimmune, Pharmaxis, Novartis and AllerGen NCE. Finally, he does not have shares in the asthma-related pharmaceutical/medical device industry, excluding pension plans, mutual funds or unit trusts..